Mineralys Therapeutics, Inc.
HealthcareNASDAQ:MLYS · NASDAQ Global Select
-$0.32 today
Vol 1.80M · Avg 1.46M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$154.7M +13.0% | -$177.8M -147.3% | -$71.9M -141.3% | -$29.8M -53.5% | -$19.4M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $59.0K +37.2% | $43.0K | $0 | $0 | $0 | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $19.3M +70.5% | $11.3M +124.0% | $5.1M +1012.1% | $455.0K +468.8% | $80.0K | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $2.7M -71.3% | $9.5M +227.5% | -$7.5M -1067.6% | $772.0K -81.1% | $4.1M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$166.0K -139.2% | $424.0K +219.4% | -$355.0K | $0 | $0 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $0 | $0 | $0 | $0 | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $2.9M -68.2% | $9.1M +227.9% | -$7.1M -1021.6% | $772.0K -81.1% | $4.1M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | -$9.9M -5.0% | -$9.4M -37.0% | -$6.9M -957.8% | -$649.0K -194.9% | $684.0K | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$142.4M +14.4% | -$166.3M -104.9% | -$81.2M -177.8% | -$29.2M -100.7% | -$14.6M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$15.0K +84.4% | -$96.0K | $0 | $0 | $0 | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$814.7M -118.2% | -$373.4M -7.3% | -$348.0M -384.9% | -$71.8M | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $425.0M -13.0% | $488.5M +160.5% | $187.5M +275.0% | $50.0M | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$389.8M -439.0% | $115.0M +171.6% | -$160.5M -637.5% | -$21.8M | $0 | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $0 | $0 | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $591.0M +409.2% | $116.1M -42.8% | $203.0M | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 | $0 | $0 +100.0% | -$1.6M | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $83.0K -67.8% | $258.0K | $0 | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $591.0M +408.9% | $116.1M -42.9% | $203.2M +58.8% | $128.0M +437.6% | $23.8M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $58.8M -9.2% | $64.8M +268.7% | -$38.4M -149.8% | $77.0M +732.6% | $9.3M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$142.4M +14.4% | -$166.4M -105.0% | -$81.2M -177.8% | -$29.2M -100.7% | -$14.6M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Apellis Pharmaceuticals, Inc.
APLS
$5.25B
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Zai Lab Limited
NASDAQ:ZLAB
$1.92B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.41B
SEC Filings
Recent regulatory filings
No filings found.
Does MLYS generate free cash flow?
Mineralys Therapeutics, Inc. (MLYS) generated -$142,431,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does MLYS produce?
Operating cash flow was -$142,416,000.00, before capital expenditures of $15,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.